Centeon albumin market withdrawal costs RPR $44 mil.; consent decree allows operations to resume.
Executive Summary
CENTEON ALBUMIN RECALL COSTS RHONE-POULENC RORER $44 MIL. IN CHARGES for fiscal 1996, the French drugmaker reported Jan. 27. RPR "incurred a significant cost during the second half of the year due to the recall of Centeon's Albuminar and the cost of lost business related to other Centeon products manufactured at this facility," the company said. Centeon is the blood products joint venture of RPR and Hoechst. Centeon's Kankakee, Ill. manufacturing facility resumed production of the blood products Jan. 22 under a consent decree with FDA ("The Pink Sheet" Jan. 27, T&G-3).